COVID-19 Seyrinde NLR, LMR, PLR, d-NLR, LeCR, LCR, NMR Biyoparametrelerinin Etkinliğinin Değerlendirilmesi

Year 2023, Volume: 12 Issue: 3, 171 - 181, 29.12.2023

Didem Çelik , Özge İnceer

https://doi.org/10.47493/abantmedj.1271653

Cited By: 1

Abstract

Amaç: Bağışıklık sisteminin şiddetli inflamatuar yanıtı, 2019 Coronavirüs hastalığının (COVID-19) ilerlemesinde ciddi bir role sahiptir. COVID-19'un immün aktivasyonunun erken teşhisinin klinik faydaları, bugüne kadar yapılan çalışmalarda vurgulanmıştır. Bu çalışmada nötrofil-lenfosit oranı (NLR), lenfosit-monosit oranı (LMR), trombosit-lenfosit oranı (PLR), türetilmiş nötrofil-lenfosit oranı (d-NLR), lenfosit-to-lenfosit oranı -C reaktif protein oranı (LCR), lökosit-C reaktif protein oranı (LeCR), nötrofil-monosit oranı (NMR) biyoendeksleri, COVID-19'un klinik seyrini tahmin etmek için değerlendirildi.
Gereç ve Yöntemler: Bu retrospektif kohort çalışmasına, Nisan ve Kasım 2020 tarihleri arasında üçüncü basamak bir hastanede yatarak tedavi görmüş, laboratuvarca doğrulanmış 383 COVID-19 vakası dahil edildi. 279 hafif ve 104 ciddi vaka dahil olmak üzere hastalar sırayla seçildi. Başvuru sırasında yapılan kan testleri incelendi. Veriler SPSS 22.0 programı kullanılarak analiz edildi ve ROC analizi yapıldı.
Bulgular: Çalışmaya alınan hastaların %44,3'ü kadındı, hastaların %99,2'sinde viral pnömoni vardı, %27,2'si ciddi hastalık klinik kriterlerini taşıyordu ve medyan yaş 58 idi. Klinik olarak ciddi hastalığı olan grupta yaş, hastanede yatış süresi, lökosit sayısı, nötrofil sayısı, ferritin, CRP, prokalsitonin, D-dimer, troponin düzeyleri daha yüksek, lenfosit, monosit sayıları daha düşüktü. LCR, CRP, d-NLR, NLR, LeCR'nin sırasıyla 15, 74,65, 2,55, 4, 133'lük eşik değerleri ile klinik şiddeti öngörmek için tanısal duyarlılıkları yüksek (AUC> 0.8) bulundu.
Sonuç: Yüksek CRP, d-NLR, NLR ve düşük LCR, LeCR klinik ciddiyetin erken belirteçleridir, bu hastalar yakın izlem ve erken müdahale için hastanede takip edilmelidir.

Keywords

COVID-19, d-NLR, LCR, LeCR, NLR

Evaluation Of the Effectiveness Of NLR, LMR, PLR, d-NLR, LeCR, LCR, NMR Bioparameters In the Course Of COVID-19

Abstract

Objective: Severe inflammatory response of the immune system has a serious role in the progression of Coronavirus disease 2019 (COVID-19). The clinical benefits of early diagnosis of immune activation of COVID-19 have been emphasized repeatedly in the trials to this date. In this study, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), derived neutrophil-to-lymphocyte ratio (d-NLR), lymphocyte-to-C reactive protein ratio (LCR), leukocyte-to-C reactive protein ratio (LeCR), neutrophil-to-monocyte ratio (NMR) biomarkers were evaluated for predicting clinical course of COVID-19.
Materials and Methods: In this retrospective cohort study, 383 laboratory-confirmed COVID-19 cases, who had been hospitalized in a tertiary care hospital between April and November 2020, were included. Patients, including 279 mild and 104 severe cases, were sequentially selected. Blood tests, conducted at the time of admission, were examined. Data was analyzed and ROC analysis was performed by using SPSS 22.0 program.
Results: 44.3% of the patients included in the study were female, 99.2% of the patients had viral pneumonia, 27.2% met clinical criteria for severe disease and median age was 58 years. Age, duration of hospitalization, white blood cell count, neutrophil count, ferritin, CRP, procalcitonin, D-dimer, troponin levels were higher and lymphocyte, monocyte counts were lower in the group with clinically severe disease. The diagnostic sensitivities of LCR, CRP, d-NLR, NLR, LeCR were found to be high (AUC> 0.8) for the prediction of clinical severity with cut-off values of 15, 74.65, 2.55, 4, 133 respectively.
Conclusion: High CRP, d-NLR, NLR and low LCR, LeCR are early predictors of the clinical severity, these patients should be under hospital follow-up for close monitoring and early intervention.

Keywords

COVID-19, d-NLR, LCR, LeCR, NLR

References

• Wang H, Xing Y, Yao X, Li Y, Huang J, Tang J, et al. Retrospective study of clinical features of Covid-19 in inpatients and their association with disease severity. Med Sci Monit 2020;26:e927674.
• National Institutes of Health Coronavirus disease 2019 (COVID-19) treatment guidelines [Internet]. [Cited 21 July 2023]. Available from: https://www.covid19treatmentguidelines.nih.gov/.
• Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504.
• Kerboua KE. NLR: A cost-effective nomogram to guide therapeutic interventions in COVID-19. Immunol Investig 2020;1-9.
• Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S, et al. Lymphocyte-to-C-reactive protein ratio: A novel predictor of adverse outcomes in COVID-19. J Clin Med Res 2020;12(7):415-422.
• Asghar MS, Kazmi SJH, Khan NA, Akram M, Khan SA, Rasheed U, et al. Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 patients in Pakistan: a single-center retrospective study in a tertiary care hospital of Karachi. Cureus 2020;12(6):e8712.
• Asghar MS, Khan NA, Kazmi SJH, Ahmed A, Hassan M, Jawed R, et al. Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis. J Community Hosp Intern Med Perspect 2020;10(6):514-520.
• Cai H, Chen Y, Chen Z, Fang Q, Han W, Hu S, et al. Handbook of COVID-19 prevention and treatment. 1st ed. Liang T, editor. China: The First Affiliated Hospital, Zhejiang University School of Medicine 2020. p. 1-84
• Infectious Diseases Society of America 2023 Guidelines on the Treatment and Management of Patients with COVID-19 Version 11.0.0. [Internet]. [Cited 29 September 2023] Available from https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/
• TC Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel bilgiler, epidemiyoloji ve tanı [Internet]. [Cited 29 September 2023]. Available from: https://covid19.saglik.gov.tr/TR-66301/covid-19-rehberi.html.
• Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39(4):561-77.
• Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. J Thromb Haemost 2020;18(6):1324-1329.
• Zhao Y, Yu C, Ni W, Shen H, Qiu M, Zhao Y, et al. Peripheral blood inflammatory markers in predicting prognosis in patients with COVID‐19 Some differences with influenza A. J Clin Lab Anal 2021;35(1):e23657.
• Ghahramani S, Tabrizi R, Lankarani KB, Kashani SMA, Rezaei S, Zeidi N, et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur J Med Res 2020;25(1):30.
• Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323(18):1775-1776
• Zhang H, Cao X, Kong M, Mao X, Huang L, He P, et al. Clinical and hematological characteristics of 88 patients with COVID‐19. Int J Lab Hematol 2020;42(6):780-787.
• Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020;71(15):762-768.
• Chan AS, Rout A. Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res 2020;12(7):448-453.